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Abstract
A relationship between vitamin D and several disorders, including Crohn's disease (CD), has recently
been proposed. Vitamin D appears to have several important actions beyond the maintenance of
bone health, including various effects on the immune system. Vitamin D deficiency has been implicat-
ed in the development of CD, and its analogues may have a role in the treatment of CD. Current re-
search also suggests a role for vitamin D in counteracting some IBD-specific complications, including
osteopenia, colorectal neoplasia, and depression. There remains a need for prospective studies to fur-
ther delineate these relationships. Given current evidence and the apparent safety of vitamin D sup-
plementation, it appears reasonable to screen for and treat vitamin D deficiency in patients with IBD.
© 2011 European Crohn's and Colitis Organisation. Published by Elsevier B.V. All rights reserved.Gastroenterology (2F59), McMa
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Vitamin D is well established as a regulator of calcium ho-
meostasis. Recently, literature has linked vitamin D to a
number of other conditions, including cancer, cardiovascular
disease, and autoimmune diseases such as multiple sclerosis,
diabetes mellitus, and Crohn's disease (CD).1 The incidence
of Crohn's disease, in general, appears to rise with increasing
distance from the equator.2 Those residing in temperate cli-
mates have less exposure to sunlight, which is responsible
for up to 95% of vitamin D production in humans.3 Vitamin
D deficiency is found in 22 to 70% of patients with CD4 and
has been proposed to play a key role in its pathogenesis.5
The aim of this review article is to explore this hypothesis,
provide an overview of the actions of vitamin D on immune
function and disease, and examine the role of vitamin D
in management of inflammatory bowel disease and its
complications.2. Physiology and immunology
Vitamin D exists in four main forms. Ergocalciferol (vitamin
D2) is synthesized following ultraviolet (UV) irradiation of a
plant steroid ergosterol.6 Cholecalciferol (vitamin D3) is pro-
duced by UV irradiation of 7-dehydrocholesterol (pre-vita-
min D3) in the skin of vertebrates, and is used as a
fortifying agent in some foods and supplements.6 Cholecal-
ciferol is hydroxylated in the liver to produce its main circu-
lating form, 25-hydroxyvitamin D (25(OH)D) (calcidiol), and
in the kidneys to its physiologically active form, 1,25-dihy-
droxyvitamin D (1,25(OH)2D) (calcitriol). Activated forms of
vitamin D are rarely given therapeutically due to a high risk
of hypercalcemia.7
Fig. 1 provides an overview of vitamin D metabolism. Di-
etary fatty fish and fortified products like milk are responsi-
ble for a small percentage of vitamin D intake. Most vitamin
D is synthesized in the skin.3 Vitamin D3 derived from ultra-
violet B radiation (UVB) or dietary intake and vitamin D2
are hydroxylated in the liver to form metabolically inactive
calcidiol. The epithelial cells in the proximal tubule of
the kidney subsequently hydroxylate calcidiol to its active
form, calcitriol.6
Binding of calcitriol to the vitamin D receptor (VDR) stim-
ulates transcription of vitamin D-responsive genes. VDRs
have been found in most organs of the body, including the
colon, small intestine, bone, breast, brain, pancreas, pitui-
tary, and muscles.8 Several other cell types in addition to
epithelial cells in the kidney have been found to convert cal-
cidiol to calcitriol, including antigen-presenting cells, para-
sympathetic ganglia, hair follicles, the cerebral cortex, and
pancreatic islet cells.8 The widespread production of calci-
triol and distribution of VDRs may help explain the increasing
number of disorders associated with vitamin D deficiency.VDRs have been found to affect transcription of at least
913 genes. Experiments in VDR-null mice have shown the
intestine to be well populated by VDRs because of its role
in calcium regulation.9,10 VDR is necessary for proper con-
trol of bone formation and renal excretion of calcium.11
Moreover, many experimental studies have implicated vita-
min D and VDR in IBD. Mucosal VDR proteins are present
considerably lower in ulcerative colitis (UC) patients
compared to healthy controls.12 Further, ulcerative coli-
tis patients who had developed colon cancer showed
lower rates of VDR expression compared to non-colon
cancer patients.12 A murine VDR knock-out model has
been associated with a spontaneous colitis.13 It has also
been demonstrated that VDR has a role in maintaining in-
tegrity of the intestinal mucosal barrier.14,15 Together,
these studies support that VDR has an important role in
control of intestinal homeostasis.
Through the VDR, vitamin D has been shown to regulate
adaptive immune responses and enhance innate immunity.20
Macrophages, dendritic cells, and activated T cells express
VDR and are responsive to calcitriol.16 Calcitriol has been
demonstrated to induce expression of antimicrobial peptides
such as cathelicidin and enhance antimicrobial activity
against pathogens such as Pseudomonas aeruginosa and My-
cobacterium tuberculosis via stimulation of toll like recep-
tors and the co-receptor CD14.17–19 Studies showed that
adding calcitriol to CD4+ T cells inhibited development of
Th1 cells and led to downregulation of several proinflamma-
tory cytokines including IL-2, IL-5, and IFN-gamma.20,21
Other studies demonstrated calcitriol decreases production
of other proinflammatory cytokines including IL-1, IL-6, IL-
8, IFN-gamma, and TNF-alpha.22,23 In contrast, calcitriol
has a role in stimulating production of regulatory T cells
expressing CTLA-4, FoxP3, IL-10, and TGFβ, all of which
have potent anti-inflammatory effects.23–25 In addition to
modulation of T-cell function, vitamin D has been shown to
affect B-cell proliferation, plasma cell differentiation, and
immunoglobulin production.263. Deficiency and autoimmune disease
Vitamin D deficiency is common, and affects an estimated
one billion people worldwide.6 Deficiency results in inade-
quate absorption of dietary calcium and is associated with
osteoporosis, rickets, and an increased risk of fractures.6
It has also been found to cause muscle weakness and in-
crease the risk for falls.6 Numerous studies have suggested
a link between vitamin D deficiency and certain malignan-
cies, including breast, prostate, and colorectal cancer.1 An
increased risk of hypertension, cardiovascular disease,
and autoimmune diseases has also been reported.1 Vitamin
D deficiency has been associated with increased preva-
lence and severity of rheumatoid arthritis, systemic lupus
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Fig. 1 Vitamin D metabolism.
399Vitamin D in IBDerythematosus, and multiple sclerosis. Additionally, vitamin
D supplementation may reduce the risk of developing some
autoimmune disorders such as type 1 diabetes mellitus and
multiple sclerosis.27,28 Epidemiologic studies suggest pa-
tients with CD have a high prevalence of vitamin D deficien-
cy.4,29,30 Factors that may lead to deficiency in these
patients include decreased dairy product intake, malabsorp-
tion of vitamin D due to short gut syndrome or small bowel
disease, bacterial overgrowth, and use of cholestyramine
for symptom management.
4. Crohn's disease and vitamin D
Several authors have suggested the existence of a north–south
gradient wherein the incidence of CD rises with increasing lat-
itude north and south of the equator.2,31 One environmental
factor that may explain this gradient is sunlight, as latitude in-
fluences the duration and intensity of sunlight exposure. A
large population study found high sun exposure to be associat-
ed with a significantly decreased incident risk of CD.32 Pa-
tients with less sun exposure have been reported to havelower serum 25(OH)D levels and more active disease.33 Some
population studies have suggested birth during summer
months to be associated with a lower risk of developing
CD,34,35 possibly from increased in utero or maternal vitamin
D. Occupationswith higher outdoor exposure are also reported
as protective against development of CD.36 A large prospec-
tive study found those who consumed more than 400 IU daily
had a significantly lower incidence of IBD than those consum-
ing less than 100 IU daily.37 Overall, these observations sup-
port the hypothesis that sunlight exposure and higher vitamin
D intake reduces the risk of CD.
5. Crohn's disease, NOD2, and vitamin D
Development of CD has been associated with variants in the
NOD2/CARD15/IBD1 gene.16 NOD2 encodes a protein that
recognizes muramyl dipeptide (MDP), a bacterial peptidogly-
can breakdown product. Some NOD2 variants associated
with CD have been associated with defects in the ability to
detect and process intracellular pathogens by the innate im-
mune system.24 NOD2 induction by calcitriol, followed by
400 N. Narula, J.K. Marshallincubation with MDP, was shown to stimulate NF-kB and in-
duce DEFB2/HBD2 expression.38 This synergistic response
was demonstrated in macrophages from a donor with wild
type NOD2, but absent in patients with CD with non-
functional NOD2 variants. These studies suggest a relation-
ship between vitamin D deficiency and the genetics of CD.6. Vitamin D therapy in Crohn's disease
To date, only one randomized placebo-controlled clinical
trial has been reported assessing the benefits of oral vitamin
D3 treatment in CD. Jørgensen et al. enrolled 108 patients
with CD in remission to calcium 1200 mg daily and either
1200 IU of vitamin D3 or placebo daily for 12 months.39
Oral vitamin D3 treatment increased serum 25(OH)D levels
from a mean of 69 nmol/l to 96 nmol/l (pb0.001) after
3 months.39 Baseline levels and concomitant medication
profiles were similar. A non-significant trend to lower re-
lapse rate was observed in patients treated with vitamin D3
(6/46 (13%) vs. 14/48 (29%), p=0.056).39 The authors specu-
lated the trial had insufficient power to detect statistical
significance, as relapse rates observed on placebo were
lower than expected. Furthermore, at the time the study
was planned, 1200 IU daily of vitamin D3 was considered to
be a high dose, but since then, more than 2000 IU daily has
been shown to be safe without risk of hypercalcemia.40
The same authors conducted a cross-sectional study in 182
patients with CD and found that patients who took oral vita-
min D supplementation had lower Crohn's Disease Activity
Index scores (CDAI) (p=0.07) and serum CRP levels
(pb0.01) than those not supplemented.41
Miheller et al. conducted a prospective cohort study of
1,25(OH)2D and 25(OH)D for 6 weeks in 37 patients with
CD. Although the primary focus of this study was on bone
turnover, significant reductions in CDAI scores and CRP
levels from baseline were noted in the group treated with
1,25(OH)2D but not in those using 25(OH)D.42 After
12 months, the two groups were similar with regards to
CDAI and CRP, but the study fails to report whether these pa-
rameters were lower than at baseline.
As the biological effects of 1,25(OH)2D require binding to
VDR to activate transcription of vitamin D-responsive genes,
novel VDR agonists are being studied. These vitamin D ana-
logues may have higher efficacy and a lower risk of hypercal-
cemia than conventional vitamin D therapies.43 Early studies
involving human cells have been promising. The VDR agonist
TX527 was shown to inhibit cell proliferation and TNF-alpha
production in peripheral blood mononuclear cells (PBMCs)
from CD patients.44 Another VDR agonist, BXL-62, has been
shown in vitro to inhibit pro-inflammatory cytokines in
PBMCs and lamina propria mononuclear cells from IBD pa-
tients, and in vivo demonstrated recovery of clinical symp-
toms of colitis in mice after intra-rectal administration.45
Clinical trials involving humans are yet to be reported.7. Benefits of vitamin D for IBD patients
Vitamin D therapy may offer additional benefits to IBD
patients including improving bone health, reducing the risk
of colorectal cancer and treating depressive symptoms.7.1. Bone health
Approximately 50% of CD patients will develop osteopenia
and a further 13% will progress subsequently to osteoporo-
sis.46 Glucocorticoid treatment was believed to have been
a major contributor to bone mineral loss but newer evidence
suggests their role has been overestimated.47–51 Increased
bone resorption is felt to be partially responsible for pediat-
ric IBD patients not achieving their full skeletal growth po-
tential.48,49,52,53 Bone mineral loss leads to osteoporosis,
fractures, and skeletal morbidity, all of which may be
avoided through early supplementation with vitamin D and
calcium.54 A meta-analysis by the Cochrane Collaboration
did not find vitamin D in various forms by itself to have a sta-
tistically significant effect on fracture incidence (RR 1.01, CI
0.93–1.09).55 Vitamin D and calcium together significantly
reduced the risk of hip fracture incidence (RR 0.84, CI
0.73–0.96) but did not affect non-vertebral fracture inci-
dence (RR 0.95, CI 0.90–1.00).55 Birshoff-Ferrari et al. ex-
amined the relationship of vitamin D3 supplementation and
separated analysis into higher-dose studies (vitamin D3
doses of 700–800 IU/day) and those using low-dose supple-
ments (doses of 400 IU/day). They found the higher-dose vi-
tamin D3 combined with calcium (500 to 1200 mg/day)
decreased hip fractures by 26% (RR 0.74, CI 0.61–0.88) and
non-vertebral fractures by 23% (RR 0.77, CI 0.68–0.87).56
The combination of calcium and vitamin D to prevent and
treat glucocorticoid-induced osteoporosis has been studied.
A randomized trial of 103 patients starting glucocorticoid
therapy found those who took calcitriol (mean dose 25 IU/
day) in addition to calcium to have reduced spinal bone loss
compared to the calcium monotherapy (−1.3% vs. −4.3%,
p=0.035).57 However, a randomized placebo-controlled trial
in IBD patients with osteoporosis and a history of glucocorti-
coid use did not reveal any significant improvement in bone
density after one-year of daily supplementation with 250 IU
of vitamin D3 and 1000 mg of calcium.58
The evidence is inconsistent on vitamin D's role in fracture
and bone loss prevention. However, calcium and vitamin D,
when used together at adequate doses, have preventative
benefits including improved bone health and reduced fracture
risk. Their role in treatment of glucocorticoid-induced osteo-
porosis seems limited, perhaps because these agents are not
able to restore damaged bone architecture.597.2. Colorectal cancer
The risk for ulcerative colitis-associated colorectal cancer is
increased at least 2-fold over the normal population.60 An in-
verse relationship between UV exposure and colorectal can-
cer risk was first suggested approximately 30 years ago.61
Since then, numerous experimental studies have suggested
1,25(OH)2D is able to inhibit growth and induce differen-
tiation of several epithelial cancer cell lines, including
colonocytes.62–64 A meta-analysis of case–control studies sug-
gested patients with serum 25(OH)D levels≥83 nmol/l had
a 50% lower risk of colorectal cancer than those with
levelsb30 nmol/l.65 A systematic review by Gorham et al.
reported a vitamin D intake of 1000 IU/day to be associated
with a 50% reduction in colon cancer risk compared with an in-
take less than 100 IU/day.66 Many of the studies included
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trast, the Women's Health Initiative Investigators reported
no significant difference in colon cancer risk among women
receiving both calcium (1000 mg/day) and vitamin D3
(400 IU/day) compared to those receiving placebo over a
seven year period.67 However, this study used relatively low
doses of vitamin D3, whereas other studies have suggested
doses of 1000 IU daily are required to reduce colorectal can-
cer risk.66 Follow-up may also have been too short as most
cases of colorectal cancer develop over greater than ten
years. There is strong in vitro and ecological data to support
a possible role for vitamin D in reducing colorectal cancer
risk, but a large well-designed RCT using higher vitamin D
doses (at least 1000 IU daily) and a longer follow up period
would be needed to establish a causal relationship between
vitamin D deficiency and colorectal cancer.7.3. Mood disorders
Depression is common among IBD patients for several rea-
sons including debilitating symptoms, side effects of medica-
tions, and altered physical appearance due to surgeries.
Numerous studies have reported significantly higher levels
of anxiety and depressive symptoms among IBD patients
compared to healthy control groups.68–71 Anxiety and de-
pression can lead to more disability and functional impair-
ment than symptoms of IBD.72,73 Furthermore, anxiety and
depression may be risk factors for disease exacerbation or
failure to respond to medical therapies.74,75 Conventional
therapies for depression have a number of side effects that
may be particularly troublesome for IBD patients, including
nausea, vomiting, and diarrhea.76
Mood disorders including seasonal affective disorder
often demonstrate a seasonal rhythm, and several studies
have investigated a link between vitamin D and depression.
Wilkins et al. reported vitamin D deficiency was significantly
associated with mood disorders in a group of elderly subjects
(OR 11.69, CI 2.04–66.86).77 Fibromyalgia patients with vi-
tamin D deficiency were reported to have more symptoms
of depression and anxiety than those with normal levels of
vitamin D.78 Another study reported lower levels of vitamin
D in patients with depression compared to healthy con-
trols.79 Experimental studies have suggested vitamin D is
crucial for brain development and function, and vitamin D
receptors and the enzymes necessary for hydroxylation of vi-
tamin D are located throughout the central nervous
system.80–82
A few studies have examined the impact of vitamin D sup-
plementation on mood with divergent results. Vieth et al.
randomized vitamin D deficient outpatients in thyroid clinics
to 600 IU or 4000 IU vitamin D daily for six months and
reported the higher dose significantly improved patient
scores on a well-being scale compared to the lower dose.83
Jorde et al. studied overweight subjects and found those
with vitamin D deficiency had significantly higher Beck De-
pression Inventory (BDI) scores.84 Patients given vitamin D,
either 20,000 IU or 40,000 IU per week, had significant im-
provements in their BDI scores after one year, but no im-
provement was demonstrated in the placebo group. In
contrast, Harris et al. treated 250 healthy women with
400 IU of vitamin D daily for one year and did notdemonstrate any improvement in mood scores.85 Overall,
these observations do support a relationship between vita-
min D and symptoms of depression, but studies reported
thus far are limited by small sizes, inclusion of patients with-
out mood disorders, and variability of vitamin D dosing and
outcome measures.8. Optimization and safety of vitamin D
There continues to be much debate about optimal levels of
serum 25(OH)D, and different health benefits may require
different target levels. Canadian osteoporosis guidelines
state that vitamin D levels are sufficient when greater than
75 nmol/l, insufficient between 25 and 75 nmol/l, and defi-
cient at levels less than 25 nmol/l.40 Vitamin D status is de-
termined by measuring 25(OH)D levels, as it has a longer
half life and represents stores of vitamin D better than ac-
tive calcitriol.40,86 Although a cut-off value has been estab-
lished at 75 nmol/l, 25(OH)D levels greater than 78 nmol/l
are needed to avoid increases in parathyroid hormone, and
calcium and phosphate absorption is maximized at values
above 85 nmol/l.87 Further, levels of at least 90 nmol/l
have been suggested for genomic stability and cancer pre-
vention.87 Authors are conflicted over the optimal minimal
serum 25(OH)D level for bone health, as many agree levels
between 70 and 80 nmol/l are necessary to reduce risk of
fractures, but some believe levels as low as 50 nmol/l may
be sufficient.88 Thus there is no consensus yet regarding an
optimal vitamin D level.
Vitamin D excess can result in increased intestinal calci-
um absorption and result in hypercalcemia, nephrocalcino-
sis, and renal injury.86 Symptoms of hypercalcemia may
include polyuria, polydipsia, nausea, vomiting, constipation,
hypertension, and altered level of consciousness or coma.8
Excessive sunlight does not result in toxicity.86 Vitamin D
toxicity can occur at serum 25(OH)D concentrations greater
than 200 nmol/l and sustained intake of 40,000 IU/day may
lead to this.86 Literature suggests that doses up to
12,500 IU/day can be tolerated without development of tox-
icity.86 Certain populations, including those with primary
hyperparathyroidism and granulomatous diseases such as
sarcoidosis or tuberculosis, may become hypercalcemic in
response to any increase in vitamin D nutrition, and in
these patients, it may be prudent to avoid supplementation
of vitamin D or diligently monitor levels.89–91
Oral supplementation is recommended for treatment of
vitamin D insufficiency and deficiency, and cholecalciferol
is more potent and longer-acting than ergocalciferol.8 Cana-
dian guidelines recommend treatment based on patient risk
profiles. Patients at low risk of consequences from vitamin
D deficiency (age less than 50 years and no comorbities af-
fecting vitamin D absorption or action) should be supplemen-
ted at doses up to 1000 IU daily without monitoring of serum
25(OH)D levels.40 Patients at moderate risk (age of 50 years
or older, with or without osteoporosis, but without comor-
bidities affecting vitamin D absorption or action) can be sup-
plemented up to 2000 IU daily without monitoring of serum
25(OH)D levels. People at high risk, including those with re-
current fractures, bone loss, and/or cormorbid conditions
affecting vitamin D absorption or action, should have base-
line serum 25(OH)D levels measured, and supplementation
402 N. Narula, J.K. Marshallshould be initiated and adjusted based on serum 25(OH)D
levels.40 A weekly dose of 10,000 IU of vitamin D3 may be
more convenient for patients and physicians may use vitamin
D2 at a dose of 50,000 IU monthly or more frequently if nec-
essary as this is acceptable for patients with severe deficien-
cy.6,40 Intermittent high dose therapy has been tried in a
small cohort of pediatric IBD patients with single doses up
to 800,000 IU administered safely and effectively, however
larger studies with longer follow-up would be necessary be-
fore this practice can be recommended.939. Conclusions
Recent literature supports an association between vitamin D
and CD. Vitamin D deficiency may have an impact on the de-
velopment of CD and subsequent disease activity. Further-
more, vitamin D and VDR agonists have potential as
treatment options for CD. Patients with IBD are prone to sev-
eral complications including osteoporosis, colorectal cancer,
and depression, which can often be more debilitating than
the primary disease itself. Vitamin D appears to have a role
in prevention and/or treatment of these comorbidities.
Considering all the evidences linking vitamin D to CD, it is
essential that further research on this topic be undertaken
by the research community. Large, prospective, random-
ized, placebo-controlled, double-blinded clinical trials are
necessary to determine the role of vitamin D therapies in
prevention and treatment of CD. In the absence of such evi-
dence, the existing literature would suggest that gastroen-
terologists should screen for and treat vitamin D deficiency
or insufficiency in patients with IBD. An optimal level for pa-
tients with IBD remains unknown but targeting serum 25(OH)
D levels between 75 and 150 nmol/l appears safe and may
have benefits for IBD, some of its complications, and other
chronic disorders.Disclosure
The authors, Neeraj Narula and John K. Marshall, do not be-
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